Paola Kučan Brlić

ORCID: 0000-0002-9178-9128
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cytomegalovirus and herpesvirus research
  • Immune Cell Function and Interaction
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Galectins and Cancer Biology
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Toxoplasma gondii Research Studies
  • Viral Infections and Immunology Research
  • Herpesvirus Infections and Treatments
  • Signaling Pathways in Disease
  • vaccines and immunoinformatics approaches
  • Viral Infections and Vectors
  • Prion Diseases and Protein Misfolding
  • Immune cells in cancer
  • Gut microbiota and health
  • Virus-based gene therapy research
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Circular RNAs in diseases
  • Infectious Encephalopathies and Encephalitis
  • Diet and metabolism studies
  • RNA Interference and Gene Delivery
  • SARS-CoV-2 detection and testing
  • Virology and Viral Diseases
  • Gastrointestinal Tumor Research and Treatment

University of Rijeka
2016-2025

The use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack tumor specificity.We stained human natural killer cells using fusion proteins composed the extracellular portion various markers fused Fc IgG1, and identified Nectin4 as novel TIGIT ligand. Next, we generated blocking antibody demonstrated its efficacy inhibitor in killing assays vivo.We identify be ligand TIGIT. We showed that,...

10.1136/jitc-2019-000266 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-06-01

The poliovirus receptor (PVR) is a ubiquitously expressed glycoprotein involved in cellular adhesion and immune response. It engages the activating DNAX accessory molecule (DNAM)-1, inhibitory TIGIT, CD96 with both functions. Human cytomegalovirus (HCMV) down-regulates PVR expression, but significance of this viral function vivo remains unknown. Here, we demonstrate that mouse CMV (MCMV) also surface PVR. m20.1 protein MCMV retains endoplasmic reticulum promotes its degradation. A mutant...

10.1084/jem.20151899 article EN The Journal of Experimental Medicine 2016-08-08

Possible early detection of people at increased risk for severe COVID-19 clinical course is extremely important so that appropriate therapy can be initiated promptly to prevent numerous deaths. Our study included 45 patients treated Dubrava University Hospital, with analysed from medical records and stool samples collected determination the gut microbiota diversity using 16S rRNA analysis. Sequencing was successful 41 belonging four groups (WHO guidelines): 12 samples—critical, 12—severe,...

10.3390/v17040520 article EN cc-by Viruses 2025-04-02

Cytomegalovirus (CMV) infection poses risks to newborns, necessitating effective therapies. Given that the damage includes both viral of brain cells and immune system-related damage, here we investigate involvement cellular prion protein (PrP), which plays vital roles in neuroprotection regulation. Using a murine model, show role PrP tempering neonatal T cell immunity during CMV infection. PrP-null mice exhibit enhanced control through elevated virus-specific CD8 responses, leading reduced...

10.1038/s41467-024-51931-4 article EN cc-by-nc-nd Nature Communications 2024-09-05

Congenital human cytomegalovirus (HCMV) infection may cause life-threatening disease and permanent damage to the central nervous system. The mouse model of CMV is most commonly used study mechanisms pathogenesis. While essential limit (MCMV) replication, inflammatory responses, particularly IFNγ TNFα, neurodevelopmental abnormalities. Other soluble mediators immune response in tissues remain largely unexplored. To address this gap, we quantified 48 response, including 32 cytokines, 10...

10.3390/v16020208 article EN cc-by Viruses 2024-01-30

Studies assessing the dynamics and duration of antibody responses following SARS-CoV-2 infection or vaccination are an invaluable tool for schedule planning, assessment risk groups management pandemics. In this study, we developed employed ELISA assays to analyze humoral Nucleocapsid Spike proteins in vaccinated health-care workers (HCW) critically ill COVID-19 patients. Sera more than 1000 HCWs patients from Clinical Hospital Center Rijeka were tested across a one-year period, encompassing...

10.3390/v14091966 article EN cc-by Viruses 2022-09-04

Cytomegaloviruses (CMVs) are ubiquitous pathogens known to employ numerous immunoevasive strategies that significantly impair the ability of immune system eliminate infected cells. Here, we report single mouse CMV (MCMV) protein, m154, downregulates multiple surface molecules involved in activation and costimulation We demonstrate m154 uses its cytoplasmic tail motif, DD, interfere with adaptor protein-1 (AP-1) complex, implicated intracellular protein sorting packaging. As a consequence...

10.7554/elife.50803 article EN cc-by eLife 2020-01-13

In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose serious threat human health and economy. Further advancement in research is necessary requires availability of quality molecular tools, including monoclonal antibodies. Here, we present development characterization collection over 40 new antibodies directed against different SARS-CoV-2 proteins. Recombinant proteins were expressed, purified, used as immunogens. Upon specific hybridomas, obtained antibody...

10.3390/v14020443 article EN cc-by Viruses 2022-02-21

Abstract The poliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is key regulator of activation, that modifies function through multiple mechanisms. Increased levels PVR expression on tumor cells have been associated with anti-PD-(L)1 therapy in clinical settings, while loss led reduced growth pre-clinical models. Targeting using blocking mAbs offers an attractive therapeutic approach for patients advanced cancer. NTX-1088...

10.1158/2326-6074.tumimm21-p075 article EN Cancer Immunology Research 2022-01-01

<h3>Background</h3> Poliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is key regulator of activation, that modifies function through multiple mechanisms. Increased PVR expression levels on tumor cells have been associated with anti-PD-(L)1 therapy, while loss led reduced growth. Targeting using mAbs offers an attractive therapeutic approach for patients advanced cancer, who are not responding other ICIs.NTX-1088...

10.1136/jitc-2021-sitc2021.254 article EN Regular and Young Investigator Award Abstracts 2021-11-01
Coming Soon ...